Skip to main content
. 2021 Sep 1;19:190. doi: 10.1186/s12916-021-02068-4

Fig. 3.

Fig. 3

Homologous recombination repair deficiency correlates with ACT chemotherapy benefits. A, C Kaplan-Meier graphs of HRD status on OS (A) and FFI (C). Statistical significance was calculated using the log-rank test. B Conceptual depiction of the TNBC patients undergoing ACT chemotherapy. D Forest plot illustrating the HR (95% CI) for FFI calculated using the multivariate Cox proportional hazard models. HR, hazard ratios; CI, confidence interval. E Distribution of ACT sensitive (light colour) or resistant (dark colour) in patients with HR deficiency (red) and HR proficiency (blue)